Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia
This study has been completed.
Sponsors and Collaborators: Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by: Radboud University
ClinicalTrials.gov Identifier: NCT00253929
  Purpose

The endogenous nucleoside adenosine can induce various cardiovascular and neurohumoral effects by stimulation of specific adenosine receptors. taken together these effects protect against ischaemia-reperfusion injury of (myocardial)muscles and agsinst the development of atherosclerosis. Genetic variations in genes encoding for adenosine receptors or for enzymes involved in the formation or breakdown of adenosine could potentially modulate these effects. In this study, we aim to determine the functional effects of two frequent genetic polymorphisms in the adenosine receptor and AMPdeaminase (involved in the formation of adenosine) on the vascular effects of adenosine.


Condition Intervention
Blood Flow in Healthy Volunteers
Drug: Intra-arterial infusion of adenosine
Drug: intra-arterial infusion of caffeine
Drug: intra-arterial infusion of acetylcholine
Drug: intra-arterial infusion of sodium nitroprusside
Procedure: Occlusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes

MedlinePlus related topics: Caffeine
Drug Information available for: Acetylcholine Acetylcholine chloride Adenosine Sodium nitroprusside Nitroprusside 3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione Caffeine citrate
U.S. FDA Resources
Study Type: Interventional
Study Design: Diagnostic, Non-Randomized, Open Label, Active Control, Parallel Assignment, Pharmacodynamics Study
Official Title: The Influence of the 1976T>C Polymorphism in the Adenosine A2A Receptor Gene on Adenosine-Induced Vasodilation and the Influence of the 34C>T Polymorphism in the AMP Deaminase Gene on Post-Occlusive Reactive Hyperemia.

Further study details as provided by Radboud University:

Primary Outcome Measures:
  • A2A: adenosine- and caffeine induced vasomotion (blood flow)
  • AMPD:post-occlusive reactibe hyperemic blood flow

Estimated Enrollment: 100
Study Start Date: November 2005
Estimated Study Completion Date: February 2006
Detailed Description:

The endogenous nucleoside adenosine can induce various cardiovascular and neurohumoral effects by stimulation of specific adenosine receptors. taken together these effects protect against ischaemia-reperfusion injury of (myocardial)muscles and agsinst the development of atherosclerosis. Genetic variations in genes encoding for adenosine receptors or for enzymes involved in the formation or breakdown of adenosine could potentially modulate these effects. In this study, we aim to determine the functional effects of two frequent genetic polymorphisms in the adenosine receptor and AMPdeaminase (involved in the formation of adenosine) on the vascular effects of adenosine.

In 100 healthy young volunteers, we will determine the genotype of the adenosine A2A receptor gene. We expect to find approximately 15 subjects with the 1976T>C polymorphisms. It is known that this polymorphism is associated with an increased neuropsychological sensitivity to caffeine administration.

We will explore whether this polymorphism is associated with a different vasodilating response to the administration of adenosine and caffeine into the brachial artery. Blood flow will be measured with venous occlucion plethysmography.

Secondly, we will also determine the genotype of the AMPD1 gene. We expect to find 15 subjects with the 34C>T mutation, which is a loss-of-function-mutation. Cardiovascular patients with this mutation are known to have a survival benefit. We will explore whether the post-occlusive reactive hyperemia in the forearm is potentiated, because during ischaemia, more adenosine is formed in these subjects.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18-40 year

Exclusion Criteria:

  • hypertension
  • diabetes
  • cardiovascular or pulmonary disease
  • asthma
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00253929

Locations
Netherlands, Gelderland
Radboud University Nijmegen Medical Centre
Nijmegen, Gelderland, Netherlands, 6500HB
Sponsors and Collaborators
Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
Principal Investigator: Gerard Rongen, MD, PhD Radboud University
Principal Investigator: Paul Smits, MD, PhD Radboud University
  More Information

Publications indexed to this study:
Study ID Numbers: SNPAdenosine, ZonMw Nr. 920-03-249
Study First Received: November 11, 2005
Last Updated: April 4, 2007
ClinicalTrials.gov Identifier: NCT00253929  
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Radboud University:
adenosine
polymorphisms
blood flow
adenosine A2a receptor
AMP deaminase

Study placed in the following topic categories:
Nitric Oxide
Caffeine citrate
Hyperemia
Nitroprusside
Vascular Diseases
Caffeine
Acetylcholine
Healthy
Adenosine

Additional relevant MeSH terms:
Neurotransmitter Agents
Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Cardiovascular Agents
Antihypertensive Agents
Cholinergic Agents
Pharmacologic Actions
Nitric Oxide Donors
Sensory System Agents
Therapeutic Uses
Cardiovascular Diseases
Anti-Arrhythmia Agents
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 14, 2009